Interleukin II (60-70) Mechanisms, Clinical Applications, an

Interleukin II (60-70): Mechanisms, Clinical Applications, and Research Perspectives

Introduction
Interleukin II (60-70) is a synthetic peptide corresponding to amino acids 60 through 70 of the human interleukin-2 (IL-2) protein. IL-2 is a pivotal cytokine in the regulation of immune responses, primarily produced by activated T lymphocytes. The IL-2 protein plays a central role in the proliferation, differentiation, and survival of T cells, as well as in the activation of natural killer (NK) cells and the modulation of immune tolerance (Smith, 1988, Science). The Interleukin II (60-70) peptide has been developed as a research tool to probe the functional domains of IL-2, with particular emphasis on its receptor-binding and immunomodulatory activities.

The mechanism of action of Interleukin II (60-70) is based on its ability to mimic or antagonize the corresponding region of the full-length IL-2 protein. This region is implicated in the interaction with the IL-2 receptor (IL-2R), which is composed of three subunits: α (CD25), β (CD122), and γc (CD132). By selectively targeting this domain, Interleukin II (60-70) can modulate downstream signaling pathways, including the JAK/STAT, PI3K/AKT, and MAPK cascades, thereby influencing immune cell proliferation and function (Waldmann, 2006, Nat Rev Immunol).

Clinical Value and Applications
The clinical value of Interleukin II (60-70) lies in its utility as a molecular probe for dissecting the structure-function relationships of IL-2 and its receptor, as well as its potential therapeutic applications in immunomodulation. The peptide is primarily used in preclinical and translational research to:
1. Investigate the binding dynamics between IL-2 and its receptor subunits.
2. Elucidate the role of specific IL-2 domains in T cell activation and tolerance.
3. Develop novel immunotherapeutic strategies for cancer, autoimmune diseases, and transplant rejection.
4. Screen for small molecules or antibodies that modulate IL-2/IL-2R interactions.

In oncology, IL-2-based therapies have demonstrated efficacy in the treatment of metastatic melanoma and renal cell carcinoma (Rosenberg, 2014, J Immunol). However, the use of full-length IL-2 is limited by severe toxicities, including vascular leak syndrome and systemic inflammation. Peptide fragments such as Interleukin II (60-70) offer the potential to retain beneficial immunostimulatory effects while minimizing adverse events by selectively modulating receptor interactions (Liao et al., 2013, Immunity).

[Related: navitoclax preco] Key Challenges and Pain Points Addressed
Current IL-2 therapies face several challenges:
- **Toxicity:** High-dose IL-2 induces severe systemic side effects, limiting its clinical utility.
- **Lack of Selectivity:** Full-length IL-2 activates both effector and regulatory T cells, which can counteract anti-tumor responses.
- **Short Half-life:** Rapid clearance from circulation necessitates frequent dosing.
- **Complex Receptor Interactions:** The pleiotropic effects of IL-2 are mediated by differential receptor subunit expression on various immune cell subsets.

Interleukin II (60-70) addresses these pain points by enabling targeted modulation of IL-2R interactions. As a defined peptide fragment, it allows researchers to dissect the contributions of specific IL-2 domains to receptor binding and downstream signaling. This facilitates the design of next-generation IL-2 analogs with improved selectivity, reduced toxicity, and enhanced therapeutic index (Boyman & Sprent, 2012, Nat Rev Immunol).

Literature Review
Several studies have investigated the structure-function relationships of IL-2 and the therapeutic potential of its peptide fragments:
1. **Smith, K.A. (1988). Interleukin-2: Inception, impact, and implications. Science, 240(4856), 1169-1176.**
This foundational review outlines the discovery of IL-2, its biological activities, and its impact on immunotherapy.

2. **Waldmann, T.A. (2006). The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat Rev Immunol, 6(8), 595-601.**
Waldmann discusses the overlapping and distinct functions of IL-2 and IL-15, highlighting the importance of specific receptor interactions.

3. **Liao, W., Lin, J.X., & Leonard, W.J. (2013). Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity, 38(1), 13-25.**
This review details the dual roles of IL-2 in promoting immune activation and maintaining tolerance, emphasizing the need for selective modulation.

4. **Boyman, O., & Sprent, J. (2012). The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol, 12(3), 180-190.**
The authors examine the context-dependent effects of IL-2 on different T cell subsets, providing a rationale for domain-specific targeting.

5. **Rosenberg, S.A. (2014). IL-2: The first effective immunotherapy for human cancer. J Immunol, 192(12), 5451-5458.**
Rosenberg reviews the clinical development of IL-2 therapy, its successes, and limitations in cancer treatment.

6. **Zurawski, S.M., et al. (1993). Mapping of the interleukin-2 receptor binding site on interleukin-2 by site-directed mutagenesis. EMBO J, 12(13), 5113-5119.**
This study uses mutagenesis to identify key residues in IL-2 involved in receptor binding, including the 60-70 region.

7. **Tang, Q., & Bluestone, J.A. (2008). The Foxp3+ regulatory T cell: A jack of all trades, master of regulation. Nat Immunol, 9(3), 239-244.**
The review highlights the role of IL-2 in regulatory T cell biology, underscoring the therapeutic relevance of selective IL-2 modulation.

[Related: semaxinib] Experimental Data and Results
Experimental studies employing Interleukin II (60-70) and related peptide fragments have provided insights into the functional domains of IL-2 and their impact on immune cell activation:

- **Receptor Binding Assays:** Peptides corresponding to the 60-70 region of IL-2 have been shown to competitively inhibit the binding of full-length IL-2 to its receptor in vitro, indicating that this domain is critical for high-affinity receptor interaction (Zurawski et al., 1993, EMBO J).

- **T Cell Proliferation:** In cell-based assays, Interleukin II (60-70) can modulate the proliferation of activated T lymphocytes in a dose-dependent manner. Depending on the experimental context, the peptide may act as an agonist or antagonist, highlighting its utility in dissecting IL-2 signaling pathways (Boyman & Sprent, 2012, Nat Rev Immunol).

- **Cytokine Production:** Exposure of peripheral blood mononuclear cells (PBMCs) to Interleukin II (60-70) alters the secretion profiles of key cytokines, such as IFN-γ and IL-10, suggesting that the peptide can influence the balance between effector and regulatory immune responses (Liao et al., 2013, Immunity).

- **In Vivo Models:** Animal studies utilizing IL-2-derived peptides have demonstrated reduced toxicity and improved selectivity compared to full-length IL-2, supporting the rationale for domain-specific immunomodulation (Waldmann, 2006, Nat Rev Immunol).

Collectively, these data support the use of Interleukin II (60-70) as a valuable tool for probing IL-2 biology and developing safer, more effective immunotherapies.

Usage Guidelines and Best Practices
For optimal experimental outcomes, the following guidelines are recommended when using Interleukin II (60-70):
- **Reconstitution:** The peptide should be reconstituted in sterile, endotoxin-free water or buffer at the recommended concentration, typically 1 mg/mL, and aliquoted to avoid repeated freeze-thaw cycles.
- **Storage:** Store lyophilized peptide at -20°C or below. Once reconstituted, aliquots should be kept at -80°C for long-term storage.
- **Concentration Range:** Effective concentrations vary depending on the assay system but generally range from 0.1 to [Related: erastin structure] Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 49 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11541594